Kling Biotherapeutics appoints Dr. med. Michael Koslowski as Chief Executive Officer
AMSTERDAM, December 12, 2022 /PRNewswire/ — Kling Biotherapeutics, BV, a clinical company pioneering the discovery and development of novel antibody-based therapeutics, today announced the appointment of Michael Koslowski, MD as chief executive officer. dr. Koslowski will oversee Kling’s growing team of experienced drug developers and its portfolio of breakthrough programs in oncology and infectious diseases. …
Kling Biotherapeutics appoints Dr. med. Michael Koslowski as Chief Executive Officer Read More »